Trial Profile
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administered
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms HIKARI
- Sponsors Otsuka Pharmaceutical
- 23 Apr 2015 According to an Astellas Pharma media release, 4-year data from this study were presented at the Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology 2015.
- 13 Jun 2014 According to the UCB Pharmaceuticals media release, results from this trial presented at the 15th Annual Congress of the European League Against Rheumatism.
- 30 Oct 2013 Post-hoc analysis for clinical response with loading dose presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.